Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Bio-Techne ( (TECH) ) is now available.
On January 30, 2025, Bio-Techne Corporation announced the appointment of Dr. Amy Herr to its Board of Directors, starting February 1, 2025. Dr. Herr will serve on the Science & Technology Committee, bringing her expertise as a bioengineering professor and Vice President at Chan Zuckerberg Biohub Network. This appointment was part of a two-year process to replace retiring directors, highlighting Bio-Techne’s strategic focus on enhancing its board with industry experts. In its financial results for the second quarter of fiscal 2025, Bio-Techne reported a 9% increase in organic revenue, reaching $297.0 million. The Protein Sciences segment showed 8% organic growth, while the Diagnostics and Spatial Biology segment had a 12% increase. The company’s strong performance is attributed to improved biopharma end-market conditions and successful execution in cell and gene therapy workflow solutions, indicating a positive outlook for stakeholders.
More about Bio-Techne
Bio-Techne Corporation operates in the biotechnology industry, specializing in providing specialized proteins, diagnostic products, and spatial biology solutions. Their primary products include cytokines and growth factors, immunoassays, antibodies, and reagents, catering to the biopharma and academic research sectors. The company is also involved in the development and provision of diagnostics and spatial biology products for in vitro diagnostics and oncology.
YTD Price Performance: 1.50%
Average Trading Volume: 938,735
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $11.45B
For an in-depth examination of TECH stock, go to TipRanks’ Stock Analysis page.
